Prelude Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Prelude Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,200	Closed	-$773K	–	1467
2023 Q1	$773K	Buy	7,200 +4,800	+200%	+$552K	0.05%	357
2022 Q4	$264K	Buy	+2,400	New	+$156K	0.01%	847

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Prelude Capital Management's RXDX Position: Q2 2023 in Review

Prelude Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 7,200 shares — an estimated $773K sold.

Prelude Capital Management first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $773K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Prelude Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Prelude Capital Management sold 7,200 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $773K.
Prelude Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Prelude Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $773K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Prelude Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.